Table 2.
Concentrations of classic CSF AD biomarkers
| Parameter | AD (n = 52) | FTD (n = 59) | DLB/PDD (n = 53) | CONTR (n = 88) | Y-CONTR (n = 32) | Test statistics |
|---|---|---|---|---|---|---|
| Aβ1–42 (pg/mL) | 432.3 ± 172.2aaa,bb,ccc,ddd (125.0–1159.0) (n = 47) |
680.1 ± 245.2aaa (282.0–1200.0) (n = 58) |
584.9 ± 235.4bb (274.0–1327.0) (n = 51) |
803.7 ± 275.9ccc (302.0–1212.0) (n = 19) |
1014.6 ± 162.2ddd (725.0–1265.0) (n = 16) |
X2 = 62.8 P < .00001 |
| T-tau (pg/mL) | 581.5 ± 285.2aaa,bbb,ccc,ddd (108.0–1200.0) (n = 47) |
362.8 ± 190.9aaa (97.0–956.0) (n = 58) |
304.2 ± 189.7bbb (17.0–1200.0) (n = 50) |
295.7 ± 144.7ccc (126.0–680.0) (n = 19) |
185.6 ± 57.0ddd (96.0–320.0) (n = 16) |
X2 = 49.3 P < .00001 |
| P-tau181P (pg/mL) | 71.0 ± 31.7aa,bbb,ddd (16.0–152.0) (n = 47) |
52.7 ± 24.6aa (19.0–116.0) (n = 58) |
50.1 ± 24.9bbb (19.0–151.0) (n = 50) |
53.4 ± 21.7 (23.0–110.0) (n = 19) |
37.1 ± 9.7ddd (21.0–52.0) (n = 16) |
X2 = 24.1 P < .0001 |
NOTE. Data represented as mean ± SD with minimum-maximum ranges between brackets. Test statistics of the Kruskal–Wallis analysis can be found in the rightmost column, while statistically significant differences with P ≤ .005, P ≤ .001, and P ≤ .0001 after M–W U analysis with Bonferroni post hoc corrections (P ≤ .0125) are depicted by one, two, and three superscript letters, respectively. Superscript letters denote differences between following groups, a: AD and FTD, b: AD and DLB/PDD, c: AD and CONTR, and, d: AD and Y-CONTR, respectively.
Abbreviations: Aβ1–42, amyloid β peptide of 42 amino acids; AD, Alzheimer's disease; CONTR, controls; DLB/PDD, dementia with Lewy bodies/Parkinson's disease dementia; FTD, frontotemporal dementia; P-tau181P, tau phosphorylated at threonine 181; T-tau, total tau; Y-CONTR, young controls.